Opinion|Videos|September 27, 2024
Treating neuropathic corneal conditions
Medical experts discuss treating neuropathic corneal conditions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- [With new advances in treatments, certain previously untreatable conditions now have specific therapies available] Can you discuss the management of the common corneal conditions you mentioned earlier?
Advertisement
Related to this article
This week's top stories include breaking FDA approvals, insights on AI-assisted front desk management, and more.
Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using one tool consistently.
Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.
CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.
Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.
Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
2
Takeaways from this week in optometry: October 16-23
3
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
4
More than monitoring: Using AMD visits to promote healthy vision aging
5